Business Update Positive

2026-11-08 18:46

- Alkem Laboratories Limited has incorporated a subsidiary joint venture named 'Alkem Pharma Company' in the Kingdom of Saudi Arabia on 8th November, 2026. - The joint venture will engage in the manufacture, import, marketing, and distribution of pharmaceutical and nutraceutical products. - Alkem subscribed to 38,250 shares amounting to 3,825,000 SAR, acquiring a 51% controlling stake in the subsidiary.

Business Update Positive

2026-11-08 18:44

- Alkem Laboratories Limited has incorporated a joint venture subsidiary named 'Alkem Pharma Company' in the Kingdom of Saudi Arabia on 8th November 2026. - The company acquired a 51% shareholding by subscribing to 38,250 shares amounting to 3,825,000 SAR via cash consideration. - The new entity will operate in the pharmaceuticals and nutraceuticals sector to expand the company's business and market reach.

Governance Neutral

2026-11-05 16:32

- Alkem Laboratories appointed Dr. Amrut Naik as the Chief Executive Officer (CEO) and Key Managerial Personnel with effect from 11th November, 2026. - Dr. Amrut Naik has over 26 years of experience in the global pharmaceutical industry spanning branded formulations, generics, APIs, and biologics.

Business Update Neutral

2026-11-04 17:15

Concall Schedule Concall Date: November 12, 2026 Concall Time: 04:30 pm IST

Business Update Neutral

2026-11-04 16:58

Concall Schedule Concall Date: November 12, 2026 Concall Time: 04:30 pm IST

Business Update Neutral

2026-11-04 16:42

Concall Schedule Concall Date: November 12, 2026 Concall Time: 04:30 pm IST

Business Update Neutral

2026-11-04 16:17

Concall Schedule Concall Date: November 12, 2026 Concall Time: 04:30 PM IST

Governance Neutral

2026-11-04 14:06

- Board meeting scheduled on Thursday, 12th November, 2026. - Agenda to consider and approve Standalone and Consolidated Unaudited Financial Results for Q2 and half year ended 30th September, 2026.

Governance Neutral

2026-11-03 13:37

- Alkem Laboratories has appointed Dr. Amrut Naik as the Chief Executive Officer (CEO) and Key Managerial Personnel. - The appointment is effective from 11th November, 2026. - Dr. Amrut Naik brings over 26 years of experience in the global pharmaceutical industry across various portfolios.

Governance Neutral

2026-11-03 13:36

- Alkem Laboratories Limited has appointed Dr. Amrut Naik as the Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) of the company. - The appointment is effective from November 11, 2026. - Dr. Amrut Naik brings over 26 years of global pharmaceutical industry experience.

Business Update Positive

2026-10-30 15:25

- Alkem Laboratories announced that the US FDA has successfully concluded an inspection at the company's API manufacturing facility located at Mandva. - The inspection was conducted from 26th October, 2026 to 30th October, 2026. - The inspection concluded with zero Form 483 observations.

Business Update Positive

2026-10-30 15:22

- Alkem Laboratories informed that US FDA conducted an inspection at the company's API manufacturing facility located at Mandva from 26th October, 2026 to 30th October, 2026. - The inspection was successfully concluded with no Form 483 observations.

Governance Negative

2026-10-21 21:54

CRITICAL RED FLAG DETECTED

- Alkem Laboratories has approved the initiation of a forensic audit by Grant Thornton Bharat LLP. - The audit is in connection with alleged misappropriation of funds and suspected irregularities in procurement transactions by a former employee. - The objective is to investigate facts, review electronically stored information, determine root causes, and recommend corrective measures.

Governance Negative

2026-10-21 21:53

CRITICAL RED FLAG DETECTED

- Alkem Laboratories has approved the initiation of a forensic audit by Grant Thornton Bharat LLP. - The audit is in connection with a recent incident involving alleged misappropriation of funds by a former employee. - The objective is to investigate procurement irregularities, perform electronically stored information reviews, and recommend corrective measures.

Governance Neutral

2026-10-12 16:09

- Alkem Laboratories Limited has appointed Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnel effective from October 12, 2026. - Mr. Laxmikant Tiwari brings 27+ years of experience in pharmaceutical operations. - Mr. Nilesh Vartak brings over 24 years of experience in supply chain leadership.

Governance Neutral

2026-10-12 16:09

- Alkem Laboratories Limited has appointed Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnel effective from October 12, 2026. - Mr. Laxmikant Tiwari brings over 27 years of experience in pharmaceutical operations. - Mr. Nilesh Vartak brings over 24 years of experience in supply chain leadership.

Governance Neutral

2026-10-12 15:45

- Alkem Laboratories Ltd announced the appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak to senior management positions effective from 12th October, 2026. - Mr. Laxmikant Tiwari brings 27+ years of experience in pharmaceutical operations. - Mr. Nilesh Vartak brings 24+ years of experience in supply chain leadership.

Governance Negative

2026-09-24 12:44

CRITICAL RED FLAG DETECTED

- Mr. Nitin Agrawal has resigned from the position of Chief Financial Officer and Key Managerial Personnel of Alkem Laboratories Limited. - The resignation is to pursue new professional opportunities. - He will cease to hold the position effective from 30th September, 2026.

Business Update Neutral

2026-09-23 14:26

- Concall Schedule - Concall Date: 07th October, 2026 - Meeting with: HDFC Mutual Fund - Type of Meeting: In-person, One-on-One - Location: Mumbai

Business Update Neutral

2026-09-23 14:21

- Alkem Laboratories Ltd. scheduled an Analyst / Institutional Investor Meeting on 07th October, 2026. - The in-person one-on-one meeting will be held in Mumbai with HDFC Mutual Fund.

Routine Neutral

2026-09-22 17:30

- Intimation of trading window closure from September 29, 2026. - The window will reopen 48 hours after financial results for the quarter and half year ended September 30, 2026, are communicated to the Stock Exchanges.

Routine Neutral

2026-09-22 17:28

- Trading window for insiders will remain closed from September 29, 2026. - It will reopen 48 hours after the financial results for the quarter and half year ended September 30, 2026, are communicated to the Stock Exchanges.

Business Update Neutral

2026-09-21 17:46

- Alkem Laboratories Ltd. issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank plc. - The guarantee is for a Euro 49.5 Million term loan availed by M/s. Occlutech Holding AG, a step-down subsidiary in Switzerland. - This creates a contingent liability for Alkem Laboratories Ltd. if Occlutech defaults.

Business Update Neutral

2026-09-21 17:43

- Alkem Laboratories Ltd. issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank plc. - The guarantee supports a Euro 49.5 Million term loan for its step-down subsidiary, Occlutech Holding AG in Switzerland. - This represents a contingent liability for Alkem in case of default by Occlutech.

Business Update Positive

2026-09-16 11:51

- Alkem Laboratories Limited launched NeuCeno (cenobamate), an anti-seizure medication (ASM), for the treatment of partial-onset seizures in adult patients. - This is the first launch of cenobamate in India, available in multiple tablet strengths from 12.5 mg to 200 mg, offering a significant advancement in epilepsy management.

Business Update Positive

2026-09-16 11:44

- Alkem Laboratories launched NeuCeno (cenobamate) for partial-onset seizures in adults. - It's a significant advancement, first launched in India, available in 12.5mg-200mg strengths. - The company aims to improve epilepsy management and patient care.

Governance Positive

2026-09-15 21:15

- Alkem Laboratories Ltd. announced the appointment of Dr. Shubhadeep Sinha as Senior Management Personnel, effective September 15, 2026. - Dr. Sinha has over 25 years of experience in clinical development, medical affairs, and regulatory affairs.

Governance Positive

2026-09-15 21:10

- Alkem Laboratories Ltd. announced the appointment of Dr. Shubhadeep Sinha to a senior management position, effective September 15, 2026. His extensive experience of over 25 years in clinical development, medical affairs, pharmacovigilance, and regulatory affairs is expected to strengthen the management team.

Business Update Positive

2026-09-08 15:11

- Alkem Laboratories Limited launched Renocia Exo™, India's first patented Ginsenoside Exosome-based hair growth serum, on September 8, 2026. - The product is a next-generation hair regeneration therapy developed to support hair follicle health and vitality.

Business Update Positive

2026-09-08 15:09

- Alkem Laboratories Ltd. launched Renocia Exo™, India's first patented Ginsenoside Exosome-based hair growth serum. - Renocia Exo™ is a next-generation hair regeneration therapy, supporting hair follicle health and vitality. - This launch strengthens Alkem's dermatology portfolio.

Governance Positive

2026-08-27 18:45

- The 52nd Annual General Meeting (AGM) of Alkem Laboratories Ltd. was held on August 27, 2026, through Video Conferencing. - All resolutions set out in the Notice of AGM, including the adoption of financial statements for FY26, confirmation of dividend payment, and re-appointment of directors, were duly approved by the members with requisite majority.

Governance Positive

2026-08-27 18:38

- The 52nd Annual General Meeting (AGM) of Alkem Laboratories Ltd. was held on 27th August, 2026, through Video Conferencing/OAVM. - All resolutions presented at the AGM, including the adoption of audited financial statements for FY ended 31st March, 2026, and the declaration of final dividend, were duly approved by the members with requisite majority. - The re-appointment of Mr. Sandeep Singh and Mr. Sarvesh Singh as directors, and Mrs. Madhurima Singh as an Executive Director for a term of 5 years were also approved. - Additionally, the remuneration for the Cost Auditor for FY ended 31st March, 2026, was ratified.

Ownership Neutral

2026-08-26 17:25

- HDFC Mutual Fund schemes increased their aggregate holding in Alkem Laboratories Limited to 5.017% of the paid-up equity share capital as of August 24, 2026. This was a 0.021% acquisition via open market, crossing the 5% threshold.

Business Update Negative

2026-08-20 18:03

CRITICAL RED FLAG DETECTED

- Q1 FY27 Revenue from operations increased by ~11% YoY to INR3,740 crores, with India sales growing 10.3% and International sales 16%. Net Profit saw a degrowth of 21.7% YoY due to taxation reasons, while EBITDA margin was 20.5% (▲3.7% YoY). - The Daman facility received an OAI status from the U.S. FDA; management anticipates no immediate impact on U.S. supplies and expects resolution within 6-12 months. - Occlutech acquisition was completed mid-July, with an FY27 target of INR400 Cr sales and breakeven EBITDA, slightly off from previous guidance due to integration delays. U.S. CDMO operations incurred a quarterly expense of INR60 Cr, with breakeven expected in 4-5 quarters. - Full-year consolidated tax rate is guided to be 30-32%. The overall India business growth is expected to be ~12% for the year, while the U.S. business is projected for high to mid-single digit growth. - Gross margins are maintained at 66.5% to 67% for the balance of the year.

Business Update Negative

2026-08-20 18:03

CRITICAL RED FLAG DETECTED

- Q1 FY27 revenue grew ~11% YoY to INR 3,740 Cr, with India sales up 10.3% and International sales up 16%. - Q1 FY27 Net Profit (PAT) saw a degrowth of 21.7% YoY, mainly due to taxation reasons. - Daman facility received an Official Action Indicated (OAI) status from the US FDA; management expects no current supply disruption and aims for resolution in 6-12 months. - India's full-year business growth guidance (Trade + Branded Formulation) is improved to close to 12%. - US sales outlook for the full year is high single digit to mid, supported by currency; volume growth remains challenging. - US CDMO operations reported INR 60 Cr operational expenses in Q1 FY27, with breakeven targeted in 4-5 quarters at USD 25-30 Mn annual revenue. - Occlutech acquisition FY27 sales target (~INR 400 Cr with breakeven EBITDA) may be slightly delayed due to integration delays. - Denosumab biosimilar approval in the US is delayed by a few months. - Consolidated tax rate for FY27 is projected at 30-32%.

Business Update Negative

2026-08-20 18:02

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹3,740 Cr (▲11% YoY); India Sales ₹2,497 Cr (▲10.3% YoY); International Sales ₹1,222 Cr (▲16% YoY). - EBITDA margin 20.5% (▲3.7% YoY); Net Profit (PAT) degrew 21.7% YoY due to taxation reasons. - Daman facility (contributing 45% of US revenue) received US FDA OAI status; company believes it won't impact business this year and expects resolution in 6-12 months. - US CDMO business (Enzene) incurred ~₹60 Cr operational expense in Q1; targets breakeven in 4-5 quarters with annualized USD25-30 million revenue. - Occlutech acquisition integration delayed; FY27 sales target of ₹400 Cr with breakeven EBITDA expected to be "a bit off" previous guidance. - FY27 outlook for overall India business (Trade Generics + Branded Formulations) is close to 12% growth. - FY27 outlook for US business is high single-digit to mid-single-digit growth, supported by currency. - Full-year gross margin guidance maintained at 66.5-67%, with potential impact from API price increases in later quarters.

Governance Positive

2026-08-17 19:05

- A meeting of equity shareholders of Alkem Laboratories Limited was held on August 17, 2026, to approve the scheme of amalgamation with Adroit Biomed Limited. - The resolution for the amalgamation was passed with an overwhelming majority, receiving 99.9999% votes in favor.

Governance Positive

2026-08-17 19:01

- The meeting of equity shareholders for Alkem Laboratories Limited was held on August 17, 2026, to approve the Scheme of Amalgamation with Adroit Biomed Limited. - The resolution for amalgamation was passed with an overwhelming 99.9999% votes in favour.

Business Update Neutral

2026-08-14 19:15

- Alkem Laboratories Ltd. announced the availability of the audio recording for its Q1FY2027 Earnings Conference Call on the company's website.

Business Update Neutral

2026-08-14 19:11

- Audio recording of the Q1FY2027 Earnings Conference Call is available on the company's website. Its availability was announced on 14th August, 2026.

Financials Negative

2026-08-14 14:08

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹3,740.2Cr vs ₹3,371.1Cr (▲10.9% YoY) - EBITDA ₹766.1Cr vs ₹739.1Cr (▲3.7% YoY) - PAT ₹520.0Cr vs ₹664.3Cr (▼21.7% YoY) - EBITDA Margin 20.5% vs 21.9% (▼140bps)

Routine Neutral

2026-08-14 14:07

- Intimation of opening of trading window for Alkem Laboratories Limited. - The trading window will open on August 17, 2026. - This follows the communication of financial results for the quarter ended June 30, 2026 to the Stock Exchanges.

Financials Negative

2026-08-14 14:07

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹37,402 Mn vs ₹33,711 Mn (▲10.9% YoY) - EBITDA ₹7,661 Mn vs ₹7,391 Mn (▲3.7% YoY) - PAT ₹5,200 Mn vs ₹6,643 Mn (▼21.7% YoY) - EBITDA Margin 20.5% vs 21.9% (▼140bps) - Regulatory Status: Daman (India) facility received Official Action Indicated (OAI) in August 2026 for April 2026 inspection. - Management noted areas for improvement in execution, operational, and regulatory priorities, while investing in R&D, MedTech, and Biotech.

Routine Neutral

2026-08-14 14:07

- Intimation regarding the opening of the trading window for Alkem Laboratories Limited. - The trading window, which was closed for the financial results of the quarter ended June 30, 2026, will now open on August 17, 2026. - The financial results for the quarter ended June 30, 2026, were communicated to the Stock Exchanges on August 14, 2026.

Business Update Positive

2026-08-14 14:04

- Board approved setting up a new manufacturing block within the existing facility at Baddi, Himachal Pradesh. - The investment for this new block is up to INR 75 crores.

Business Update Positive

2026-08-14 14:04

- Alkem Laboratories Ltd. to set up a new block within its existing manufacturing facility at Baddi, Himachal Pradesh. - The Board has approved an investment of up to INR 75 crores for this expansion.

Financials Negative

2026-08-14 14:04

CRITICAL RED FLAG DETECTED

- Q1 FY27 Consolidated Revenue ₹37,402 Mn vs ₹33,711 Mn (▲10.9% YoY) - EBITDA ₹7,661 Mn vs ₹7,391 Mn (▲3.7% YoY) - PAT ₹5,200 Mn vs ₹6,643 Mn (▼21.7% YoY) - EBITDA Margin 20.5% vs 21.9% (▼140bps)

Financials Negative

2026-08-14 13:50

- Q1 FY27 Consolidated Revenue ₹37,401.5Mn vs ₹33,711.4Mn (▲11.0% YoY) - EBITDA ₹7,660.5Mn vs ₹7,519.8Mn (▲1.9% YoY) - PAT ₹5,209.8Mn vs ₹6,679.1Mn (▼22.0% YoY) - EBITDA Margin 20.5% vs 22.3% (▼180bps)

Financials Negative

2026-08-14 13:49

- Q1 FY27 Consolidated Revenue ₹3,740Cr vs ₹3,371Cr (▲11% YoY) - EBITDA ₹766Cr vs ₹752Cr (▲2% YoY) - PAT ₹521Cr vs ₹668Cr (▼22% YoY) - EBITDA Margin 20.5% vs 22.3% (▼180bps)

Business Update Negative

2026-08-06 16:32

CRITICAL RED FLAG DETECTED

- US FDA classified the inspection status of Alkem's Amaliya, Daman manufacturing facility as "Official Action Indicated (OAI)". - The inspection, conducted from April 20 to May 1, 2026, had resulted in seven (7) observations on Form FDA 483.

Governance Positive

2026-08-03 17:41

- Alkem Laboratories Ltd. has appointed Mr. Rajpal Singh Rana to a senior management position, effective August 03, 2026. - Mr. Rana brings over 30 years of experience in pharmaceutical marketing and sales.

Governance Neutral

2026-07-30 17:12

- The 52nd Annual General Meeting (AGM) is scheduled for Thursday, 27th August, 2026 at 11:00 A.M (IST) via Video Conferencing. - The Annual Report for FY 2025-26 has been dispatched to shareholders.

Governance Neutral

2026-07-29 20:50

- Notice of 52nd Annual General Meeting (AGM) and Annual Report for financial year 2025-2026. - AGM scheduled for Thursday, 27th August, 2026 at 11:00 a.m. - Meeting will be conducted through Video Conferencing (VC)/Other Audio-Visual Means (OAVM).

Routine Positive

2026-07-29 20:41

- Alkem Laboratories filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - Highlights: 15% reduction in GHG emissions, 22% reduction in energy consumption YoY. - All operational units are ISO 50001 and ISO 45001 certified.

Business Update Neutral

2026-07-27 14:22

- Concall Schedule - Concall Date: Friday, August 14, 2026 - Concall Time: 4:30 p.m. IST

Governance Negative

2026-07-23 13:23

CRITICAL RED FLAG DETECTED

- Dr. Jitendra Singh Huda, a Senior Management Personnel, has resigned from Alkem Laboratories Ltd. effective 23rd July 2026 to pursue professional opportunities.

Business Update Positive

2026-07-17 18:08

- Alkem Medtech Private Limited, a wholly owned subsidiary of Alkem Laboratories Ltd., has completed the acquisition of 51% to 55% of Occlutech Holding AG. - Occlutech Holding AG, a company incorporated in Switzerland, will now be a step-down subsidiary of Alkem Laboratories Ltd.

Business Update Positive

2026-07-16 14:55

- Alkem Laboratories acquired 79,36,50,794 equity shares of its wholly-owned subsidiary, Alkem Medtech Private Limited, for ₹11,00,00,00,005 on July 15, 2026. - Alkem Medtech (engaged in medical devices) plans to acquire 51-55% of Occlutech Holding AG.

Governance Neutral

2026-07-15 15:39

- Alkem Laboratories Limited to hold an equity shareholders' meeting on August 17, 2026, via electronic mode. - Purpose: To approve the Scheme of Amalgamation with Adroit Biomed Limited, as per NCLT order. - E-voting open from August 12-16, 2026.

Business Update Positive

2026-07-01 16:50

- Alkem Laboratories received favorable Orders-in-Appeal from the Commissioner of Income Tax, Appeal for Assessment Years 2018-19 to 2022-23. - The orders delete disallowances made under Section 80-IE of the Income-tax Act, 1961, involving a tax amount of ₹660.77 Crores. - The Company stated there is no material impact on its financial, operation, or other activities.

Business Update Neutral

2026-06-29 11:57

- Analyst / Institutional Investor Meeting Schedule - Meeting Date: 06th July, 2026 - Meeting with: Sprucegrove Investments - Nature: In-Person, One-on-One Meet

Business Update Neutral

2026-06-29 11:52

- Concall Schedule - Concall Date: 03rd July, 2026 - Meeting with: TA Associates (Virtual)

Business Update Positive

2026-06-29 09:40

- Alkem Medtech, a wholly owned subsidiary, executed a First Supplementary Agreement on June 26, 2026, related to its previously announced intention to acquire 51-55% of the total issued equity share capital of Occlutech Holding AG.

Routine Neutral

2026-06-24 13:18

- Trading window for Alkem Laboratories Ltd. will close from June 29, 2026, for the quarter ended June 30, 2026. - It will reopen 48 hours after the financial results are communicated to the Stock Exchanges.

Business Update Neutral

2026-06-15 18:11

- Concall Schedule - Concall Date: 19th June, 2026 - Meeting Type: Virtual

Business Update Neutral

2026-06-10 16:24

- Investor Meeting Schedule - Meeting Date: 16th June, 2026 - Analyst/Investor: Haitong Securities India Private Limited - Type of Meeting: In-person, One-on-One

Business Update Positive

2026-06-02 15:14

- Alkem Laboratories launched semaglutide in single-shot pre-filled syringes, becoming the first in India to do so. - The product is priced starting INR350 and is approved for Type 2 diabetes and obesity.

Business Update Positive

2026-06-01 16:39

CRITICAL RED FLAG DETECTED

Alkem Laboratories reported a landmark FY26 with record profitability and highest ever EBITDA, driven by strong growth in India and international businesses and successful launch of semaglutide. Management acknowledged potential near-term headwinds due to increased logistics costs, API, and packaging material prices from geopolitical instability, tempering the previous guidance of 100 basis points annual margin expansion to maintaining FY26 EBITDA margins of 20-21% for FY27. The tax rate will increase to 27-29% in FY27 due to moving to a new tax regime. Management guided for India business to grow 100-150 basis points higher than the market, US market to achieve high single-digit growth (dollar-to-dollar) plus currency gains, and ROW markets to see higher teen's growth in FY27. CEO, Dr. Vikas Gupta, is departing, and a search for a new CEO is underway. Tolvaptan is expected to launch in the US in H2 FY27.

Business Update Neutral

2026-05-28 18:31

Alkem Laboratories Limited announced on May 28, 2026, that the audio recording of its Q4FY2026 and FY2026 Earnings Conference Call is available on the company's website at https://www.alkemlabs.com/investors/earnings-call, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Routine Neutral

2026-05-28 13:45

Alkem Laboratories Ltd. announced the opening of its trading window from June 1, 2026, following the communication of the financial results for the quarter and year ended March 31, 2026, to the Stock Exchanges on May 28, 2026.

Financials Positive

2026-05-28 13:39

The Board of Directors of Alkem Laboratories Ltd. approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2026. The board recommended a final dividend of Rs. 10 per equity share for the financial year ended 31st March, 2026, to be approved at the 52nd Annual General Meeting (AGM) scheduled for August 27, 2026. The record date for the dividend is August 07, 2026. The Auditors expressed an unmodified opinion on the financial results.

Financials Positive

2026-05-28 13:35

The Board of Directors of Alkem Laboratories Ltd. approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. A final dividend of Rs. 10 per equity share for the financial year ended March 31, 2026, was recommended. The 52nd Annual General Meeting (AGM) will be held on August 27, 2026, with the record date for dividend payment fixed as August 7, 2026, and payment from September 1, 2026. Mrs. Madhurima Singh was also re-appointed as an Executive Director for five years.

Financials Positive

2026-05-28 13:35

Alkem Laboratories Ltd.'s Board of Directors approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of Rs. 10 per equity share for FY 2025-26. The 52nd Annual General Meeting (AGM) is scheduled for August 27, 2026, and the re-appointment of Mrs. Madhurima Singh as an Executive Director for five years was also approved.

Governance Neutral

2026-05-28 13:30

Alkem Laboratories Limited's Board of Directors has approved the re-appointment of Mrs. Madhurima Singh as an Executive Director for a term of 5 (five) consecutive years. The re-appointment is effective from 20th December, 2026, until 19th December, 2031, and is subject to the approval of shareholders at the ensuing Annual General Meeting.

Financials Positive

2026-05-28 13:26

Consolidated Revenue ₹3,603.32 Cr vs ₹3,143.75 Cr (▲14.61% YoY), EBITDA ₹517.39 Cr vs ₹391.29 Cr (▲32.22% YoY), PAT ₹236.46 Cr vs ₹305.86 Cr (▼22.69% YoY). EBITDA Margin 14.36% vs 12.45% (▲191bps). The Board also recommended a final dividend of Rs. 10 per equity share for FY26.

Business Update Neutral

2026-05-25 11:56

Alkem Laboratories Ltd. announced an in-person, one-on-one meeting with SBI Mutual Fund scheduled for May 29th, 2026, in Mumbai. This is an Analyst / Institutional Investor Meeting.

Business Update Neutral

2026-05-20 15:45

Alkem Laboratories Ltd. announced a conference call for investors and analysts to discuss its Q4FY26 and FY26 financial results. The call is scheduled for Thursday, May 28, 2026, at 4:30 p.m. IST, with key management personnel including the MD, CEO, and CFO participating. Motilal Oswal Securities Ltd. will host the call.

Governance Positive

2026-05-18 12:37

Alkem Laboratories Ltd. announced the appointment of Mr. Chanakya Misra to a senior management position, effective 18th May 2026. Mr. Misra brings over 25 years of professional experience across pharmaceuticals, public health, rare diseases, and healthcare ecosystems, holding an MBA and a Bachelor of Pharmacy from IIT (BHU).

Business Update Positive

2026-05-08 18:42

Alkem Laboratories Ltd. announced that the US FDA conducted an unannounced inspection at its Contract Research Organization (CRO) facility in Taloja, Maharashtra, on May 8, 2026. At the conclusion of the inspection, no Form 483 was issued, indicating a satisfactory outcome and compliance with regulatory standards.

Business Update Positive

2026-05-05 18:51

Alkem Laboratories Ltd. received a favourable Order-in-Appeal on May 4, 2026, from Commissioner (Appeals) -II CGST & C.Ex, Mumbai. The order dropped a GST demand of ₹69.65 crore, along with applicable interest and penalty, related to alleged incorrect availment of ITC/GST refund. The company stated there is no material impact on its financial, operational, or other activities.

Business Update Negative

2026-05-02 12:53

CRITICAL RED FLAG DETECTED

Alkem Laboratories Ltd. announced that its manufacturing facility at Amaliya, Daman, underwent a US FDA inspection from April 20th to May 1st, 2026. At the conclusion of the inspection, the company received a Form 483 with seven (7) observations. The company committed to addressing these observations within the stipulated timeframe.

Business Update Negative

2026-04-24 16:43

CRITICAL RED FLAG DETECTED

Alkem Laboratories received an Income Tax order on April 24, 2026, for AY 2023-24, disallowing ₹333.38 Cr in deductions and adjustments. The company states no material financial impact due to MAT credit and will appeal the order, believing it's not tenable.

Routine Neutral

2026-04-24 15:30

New Filing detected. See link for details.

Governance Negative

2026-04-24 14:34

CRITICAL RED FLAG DETECTED

Alkem Laboratories announced the resignation of Dr. Vikas Gupta, Chief Executive Officer and Key Managerial Personnel, to pursue new professional opportunities. He will continue until June 30, 2026, to ensure a smooth transition of responsibilities.

Business Update Positive

2026-04-13 15:39

Alkem Laboratories Limited has incorporated a Wholly Owned Subsidiary, 'Alkem Pharma Trading FZCO', in Dubai, UAE. This WOS, with 100% shareholding and a capital of AED 3,670,000, aims to export the Company's products to African, South East Asian, and non-UAE markets.

Routine Neutral

2026-04-10 18:08

New Filing detected. See link for details.

Business Update Positive

2026-04-07 15:27

Alkem Laboratories Ltd. launched 'A to Z Daily' on April 7, 2026, a multivitamin supplement for adults. It provides holistic nutritional support, formulated with 26 essential vitamins, minerals, and botanicals to help manage stress, improve energy, and strengthen immunity.

Ownership Neutral

2026-04-07 14:30

Basudeo N. Singh, promoter of Alkem Laboratories Limited, declared that the promoter group has not made any encumbrance on shares, directly or indirectly, during the financial year 2025-26, as per SEBI SAST Regulation 31(4).

Business Update Positive

2026-04-02 13:00

Alkem Laboratories' Board on April 2, 2026, approved increasing the investment for its greenfield formulations manufacturing facility in Ujjain from up to INR 533 crores to up to INR 1036 crores. This expanded investment will be made in a phased manner.

Governance Neutral

2026-03-31 18:47

Alkem Laboratories Ltd. announced Mr. Ravinder Chaklam superannuated from senior management on March 24, 2026. Mr. Mukesh Tiwari also ceased senior management position in the company on Oct 1, 2025, following his appointment in a wholly-owned subsidiary. Disclosure was delayed due to oversight.

Business Update Neutral

2026-03-30 17:37

Alkem Laboratories Ltd. incorporated 'Alkem Pharmaceuticals Scientific Office FZ LLC' as a Wholly Owned Subsidiary in Dubai Healthcare City, UAE, on Feb 4, 2026. The WOS, with AED 3.67M capital, will handle manufacturing and product registrations. Approvals from UAE's Ministry of Health are delayed due to regional conflict.

Governance Neutral

2026-03-27 18:11

Alkem Laboratories Limited announced the appointment of Mr. Samsher Kumar Deo as Senior Management Personnel, effective March 27, 2026. Mr. Deo has over 29 years of experience, mainly in sales functions.

Routine Neutral

2026-03-27 11:26

Alkem Laboratories Limited announced the closure of its trading window from March 30, 2026, until 48 hours after the communication of financial results for the quarter and year ended March 31, 2026, to the stock exchanges.

Business Update Positive

2026-03-21 12:17

Alkem Laboratories launched Semaglutide injection in India on March 21, 2026, for type-2 diabetes and chronic weight management under brand names "Semasize", "Obesema", and "Hepaglide". Weekly therapy starts at INR 450/-, aiming to provide an affordable and accessible treatment option.

Business Update Positive

2026-03-20 21:19

Alkem Laboratories received an EU GMP Certificate from the Malta Medicines Authority for its Daman manufacturing facility, valid for three years from December 09, 2025. This ensures compliance for manufacturing activities.

Business Update Neutral

2026-03-20 17:09

Alkem Laboratories Ltd. informed of a virtual analyst/institutional investor meeting with Millennium Capital Management scheduled for March 26, 2026, to discuss the company's business.

Business Update Positive

2026-03-18 19:57

Alkem Laboratories received an allotment letter on March 18, 2026, for 30 acres in Ujjain, MP, to set up a new greenfield manufacturing facility. The Board approved an investment of up to ₹533 crores in a phased manner.

Business Update Positive

2026-03-14 15:45

Alkem Laboratories received an EU GMP Certificate for its Baddi manufacturing facility from the Department of Pharmacy (Human Medicines) – Germany, following a November 2025 inspection. The certificate is valid for three years, ensuring continued compliance for European market access.

Business Update Positive

2026-03-06 15:38

Alkem Laboratories' wholly-owned subsidiary, Alkem Medtech, has executed a Share Purchase Agreement on March 6, 2026, to acquire a 51% to 55% equity stake in Switzerland-based Occlutech Holding AG. This updates the previous intimation from February 13, 2026.

Business Update Neutral

2026-02-20 18:31

Alkem Laboratories announced on February 20, 2026, that the video recording of an investor meet discussing Alkem MedTech's strategic way forward is now available on the company's website for investor access.

ALKEM

Alkem Laboratories Limited

Price Chart

Filing History

Unlock Full History